Puma Biotechnology Inc   (PBYI)
Other Ticker:  
Price: $4.0000 $0.01 0.251%
Day's High: $4.03 Week Perf: -8.47 %
Day's Low: $ 3.88 30 Day Perf: -18.03 %
Volume (M): 240 52 Wk High: $ 7.73
Volume (M$): $ 960 52 Wk Avg: $4.11
Open: $4.00 52 Wk Low: $2.13

 Market Capitalization (Millions $) 193
 Shares Outstanding (Millions) 48
 Employees 460
 Revenues (TTM) (Millions $) 207
 Net Income (TTM) (Millions $) 5
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 13

Puma Biotechnology Inc
Puma Biotechnology Inc. is an American biopharmaceutical company founded in 2010 and headquartered in Los Angeles, California. The company specializes in the development of innovative drugs for the treatment of cancer, with a particular focus on breast cancer, the second most common cancer in women worldwide.

Puma Biotechnology's main product candidate is Neratinib, a small molecule tyrosine kinase inhibitor (TKI) that targets HER2 (human epidermal growth factor receptor 2), a receptor that is overexpressed in approximately 20% of breast cancer patients. HER2 overexpression is associated with more aggressive tumors, higher rates of recurrence, and poorer prognosis.

Neratinib is being developed as an extended adjuvant therapy for patients with HER2-positive early stage breast cancer who have completed standard of care treatment with trastuzumab, another HER2-targeted therapy, and chemotherapy. The extended adjuvant therapy with neratinib is intended to reduce the risk of disease recurrence and improve overall survival.

Puma Biotechnology completed several pivotal clinical trials of neratinib, including the Phase III ExteNET trial, which enrolled over 2,800 patients and demonstrated a statistically significant improvement in disease-free survival compared to placebo. The company has also conducted clinical trials of neratinib in other HER2-positive cancers, including metastatic breast cancer, HER2-mutant solid tumors, and glioblastoma.

In addition to neratinib, Puma Biotechnology has a pipeline of other drug candidates in preclinical and clinical development, including PB272 (neratinib in combination with another TKI), PB357 (a novel kinase inhibitor), and PB891 (an antibody-drug conjugate).

Puma Biotechnology has a global commercialization agreement with Pierre Fabre, a French pharmaceutical company, for the commercialization of neratinib in Europe, Latin America, Africa, and select other countries. The company also has licensing agreements with various academic institutions and biotech companies for the development of its drug candidates.

The company has a market capitalization of approximately $6 billion as of August 2021 and employs approximately 200 people. Puma Biotechnology is publicly traded on the NASDAQ stock exchange under the ticker symbol PBYI.

   Company Address: 10880 Wilshire Boulevard, Suite 2150 Los Angeles 90024 CA
   Company Phone Number: 248-6500   Stock Exchange / Ticker: NASDAQ PBYI


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Business Update

Puma Biotechnology Complies with Nasdaq Listing Rule 5635(c)(4) through Inducement Awards

Published Tue, Feb 27 2024 11:30 PM UTC

Los Angeles-based biopharmaceutical company, Puma Biotechnology, Inc. (NASDAQ: PBYI), recently announced that it has granted an inducement restricted stock unit award to a new non-executive employee in order to comply with Nasdaq Listing Rule 5635(c)(4). The award covers 7,500 shares of Puma common stock and was approved by the Compensation Committee of Puma's Board of Direc...

Stock Transactions

Puma Biotechnology's Inducement Award: Attracting Top Talent and Fostering Excellence

Published Mon, Nov 6 2023 10:15 PM UTC

Puma Biotechnology, a renowned biopharmaceutical company, recently announced the approval of an inducement restricted stock unit award covering 15,000 shares of Puma common stock to a new non-executive employee. The Compensation Committee of Puma's Board of Directors gave their nod to this grant on November 1, 2023. This article delves into the significance and imp...

Puma Biotechnology Inc

Puma Biotechnology Inc Drives Positive Investor Interest with Strong Share Performance and Turnaround in Earnings

Puma Biotechnology Inc, a major player in the pharmaceutical industry, has seen a positive trend in its shares over the past week. The company's shares have gained 10.31% during this period, showing a significant increase in investor interest. Furthermore, compared to the previous year, Puma Biotechnology Inc shares have improved by 9.33%, indicating a positive growth trajectory for the company.
One of the reasons behind this upward momentum is Puma Biotechnology Inc's ability to turn its declining sales into profitability. In the most recent fiscal period, the company's earnings per share (eps) stood at $0.12, displaying positive growth compared to the preceding year. However, it is worth noting that the company's revenue declined by -1.727% to $56.12 million during the same reporting period.

Puma Biotechnology Inc

Puma Biotechnology Inc Reports Significant Decline in Q2 2023 Earnings Per Share

Puma Biotechnology Inc is a major pharmaceutical preparations company that has recently experienced a decline in revenue and profitability. In the second quarter of 2023, the company's revenue fell by 8.317% to $54.57 million, compared to the same quarter a year prior. This softness in revenue caused the company's bottom-line to tumble by -76.19% to $0.05 per share, from $0.21 per share in the previous year's quarter.
In the prior quarter, Puma Biotechnology Inc generated revenue of $52.78 million and a bottom line of $0.03 per share. However, in the second quarter of 2023, the company's net profits fell by -77.31% to $2.126 million, compared to $9.371 million in the corresponding period a year before. This significant decline in net profits reflects the challenges faced by the company during this period.

Puma Biotechnology Inc

Puma Biotechnology Inc.'s Dynamic Double-Digit Growth Sparks Investor Excitement in Recent Fiscal Period

Investors need to exercise caution when considering investing in Puma Biotechnology Inc based on its Q1 2022 financial results. While the company's return on asset (ROA) of 2.37% is an improvement from the 0% reported in the previous quarter, it is still below the average ROA of other companies in the healthcare sector. Additionally, while PBYI has shown improvement in their revenue growth and achieved a turnaround to surplus, their net profit is still relatively low.
Investors should also note that PBYI is expected to report their next financial earnings on August 03, 2023. It is important to carefully monitor the company's financial performance leading up to this date, as any unexpected changes could impact the stock price.


Puma Biotechnology Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com